This work will generate a considerable volume of data (nominally by end of Q2 2023). I wonder if tumour samples from the ~ 29 cancers identified by FTO research will be screened.
I think this data will be compelling for partnering discussions.
The scale of the screening work RACE seem to be planning potentially allows them to put together some very compelling value angles in partnership/commercialisation discussions once that data is available. I think Big Pharma will be very interested in a target they can scale to multiple indications very quickly.
Imagine if this scale of preclinical work was done before anti-PD1/PDL1 trials started that lead to Keytruda and Opdivo creating a new class of drugs. With benefit of hindsight anti-PD1/PDL1 has addressed many cancers. Anti-PD1/PDL1 would have scaled much faster than it has if this type of screening was used then.
Anti-PD1
https://www.drugs.com/history/keytruda.html
https://www.drugs.com/history/opdivo.html
https://www.drugs.com/history/libtayo.html
Anti-PDL1
https://www.drugs.com/history/tecentriq.html
https://www.drugs.com/history/bavencio.html
https://www.drugs.com/history/imfinzi.html
